Agios Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run
Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...
Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62
Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals: Q3 Earnings Snapshot
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
Agios Pharmaceuticals Q3 2026 Earnings Call Transcript
Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Will FDA Review Delay Change Agios Stock Narrative
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.